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Recombinant wild.lyp¢ protea~ of human imraunod~ficiency virus, type I [HIV. I) expressed in E. ealt was purified by i~pitattn A affinity chromo. 
tography. An till.fold purification was achieved givin|l a protea~ preparation with a sl~ei[l¢ ©nzymatic activity of approximately 3700 pmollminlt~g, 
Two proteolytically ina¢live HIV-I n'mtant protea~s (Arlt-87~Lys; Asn.fg.-,Glu) were found to bind to p©pstatin A a~tarose, and they were purl. 
fled as the wild-type pro(ease. A third mutant protcase (Arll.87.-*Glu) war apparently unabl© to bind to pepstatin A under similar conditions, 
Binding to pepstatin A indicates the binding ability of the substrate binding site and the ability to form dinners, These features may t~ used to 
purif~ and to characterize other mutated HIV-i ptotea~s, 
HIV-I protcas¢; Mutant protea~ Pcpstatin A aflhtity chromatography 
1. INTRODUCTION 
The virus encoded proteases have an essential func- 
tion in the life cycle of retroviruses [1-3]. Studies have 
been focussed on the protease of the human im- 
munodeficiency virus (HIV), the causative agent of ac- 
quired immunodeficiency syndrome [4]. As a potential 
target for chemotherapy, its enzymatic properties and 
inhibitors (for review see [5-9]) as well as its structure 
have been studied [10]. 
Also, mutants of the protease have been generated to 
identify the active site and other functionally important 
regions within the enzyme ([11-13] and references 
therein). The second conserved region, Gly-Arg-Asn at 
position 86-88, which is unique for retroviral proteases 
(PR), and is not present in pepsins, was found to be 
essential for proteolytic activity [12]. Based on the 
3-dimensional structure [10,14], an interaction by ion 
pairing of Are-87 with Asp-29 has been assumed to be 
required for enzymatic activity. 
Retroviral PRs represent a subclass of pepsin-like 
aspartic proteases and the general inhibitor pepstatin A 
was used to purify the PR o f  bovine leukaemia virus 
(BLV) by inhibitor affinity column chromatography 
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[15]. For the purification of HIV-I PR, inhibitor affini- 
ty Chromatography was established by using a peptide 
substrat¢ analogue coupled to agarose resin [16]. HIV-I 
PR is also inhibited by pepstatin A [17-20]. In this 
report, we describe pepstatin A affinity chroma- 
tography purification of HIV-1 wild-type PR and 
proteolytically inactive mutant proteases. 
2. MATERIAL AND METHODS 
2,1 Purification of recombinant HIV.I protease 
Lysates of E. co/i, expressing the HIV-I PR [21] were clarified by 
centrifugation for 30 rain at 200000 x g at 4°C. An equal volume of 
ice-cold saturated ammonium sulfate solution containing 1 mM 
dithiothreitol (DTT) was added, stirred overnight at 4°C and cen- 
trifuged for 15 rain at 15 009 × g, The pellet was resuspended in 10 ml 
of buffer A (50 mM Pipes, pH 6.8, 1 M NaCI, 1 M ammonium 
sulfate, 1 mM DTT, 1 mM EDTA, I ram Na/K-tartratco 10070 
glycerol) and centrifuged for 30 rain at 100000×g. The supernatant 
was loaded on a pepstatin A agarose (Pierce) column. After washing 
the column with 5 vols of buffer A, the PR was eluted with buffer B 
(100 mM Tris-HCl, pH 8,2, 1 mM DTT, i mM EDTA. I mM Na/K 
tartrate, 10% glycerol, 5070 ethylene glycol) at a floW rate of ! 
cm/min. 
2,2. Protease assays 
Unless noted otherwise, 1 pl of the fractions were assayed for PR 
activity using the synthetic ..~.apeptide substrate, VaI-Ser-Gln-Asn- 
Tyr-Pro-lle.Val-Gln-NH2 122], according to the procedure described 
earlier [20,21]. Assays were carried out in a total volume of 10.ul con- 
taining 3000 pmoles of substrate, 5 tzl of 2 × reaction buffer (0,5 M 
potassium phosphate, pH 6,5, 5°7o (v/v) glycerol, 1 mM DTT, i mM 
EDTA and 1.5 M ammonium sulphate), and were incubated for 30 
min at 37°C, 
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F 8 I. Purification or recombinant HIV-I wild.type and mutant protease by pepstatin A ehromatoltraphy. Fractions of wild.type pro(ease were 
assayed for proteolylic activity, and mutant protease (Mut 3-1 l; ArlpB?'Lys) was detected by Western blotting (in~ert), Lanes t and 2 show el'. 
t'lt, ent fractions at th© maximun~ ofdie protein peak monitored at 280 nm, and lanes 3-5 demonstrate fractions of the eluate, corresl:onding to
fractions 3-7, 
2,3. imntunoblott#lg 
Equal volumes of the efflue,~t and eluate fractions after pepstatin 
A chromatography were electrophoresed on 10-20% gradient ricine- 
polyacrylamide gds (Novex Experimental Technology, CA) or dot 
blotted. The proteins were transferred to 0,22 t~m nitrocellulose paper 
(Schleicher & Sch{lll) and immunoblotted using antiserum specific to 
H IV-I protease [22] preadsorbed using I: t0 Volumes of a 2 mg/ml E. 
coli lysate for 1 h at room temperature. 
3. RESULTS AND DISCUSSION 
Immobilized pepstatin A has been used in the 
purif ication of cathepsin D, pepsmogenes, renin ([23] 
and references therein), and BLV PR [15]. We defined 
conditions for purifying HIV- I  PR by pepstatin A af- 
finity chromatography, which provides a fast procedure 
for isolating recombinant HIV-1 PR. The protease was 
bound to pepstatin A agarose at a high salt concentra- 
t ion, pH 6.8, and  was eluted from the resin at pH 8.2 
without salt as shown in Fig. 1. This result is in accor- 
dance with inhibitor studies, which indicated that the 
binding of pepstatin A is pH.dependent.  It occurs 
readily at low pHs, but is markedly reduced above pH 
7 [17,18]. In addition, high ionic strength is of  tmpor- 
tance for pepstatin binding [17]. After pepstatin A af- 
f inity chromatography,  19°70 of  PR activity was 
recovered, and the specific enzyme activity increased by 
a factor of 88, from 42 pmol/min//~g in the crude E. 
co/i lysate to 3700 pmol/min//zg after the column pro- 
cedure. Under similar conditions, the HIV-1 PR did not 
b ind to agarose beads (Bid-Gel A-0,5m, 200-400 mesh), 
demonstrat ing a specific binding to pepstatin A. Addi- 
t ional procedures involving hydrophobic interaction 
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| i 0 I 
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Fig. 2. Characterization f HIV-1 mutants proteases by pepstatin A chromatography. Mut 4-1 (Arg-87~Glu) and Mut 5+10 {Asn.88--+Glu) were 
applied to pepstatin A affinity chromatography. 100/zl of effluent and eluate fractions were tested for mutant protease by dot blotting using a 
preadsorbed HIV-I protease specific antiserum and horseradish peroxidase staining. 
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Table I 
Comlmrtm. or H IV. I wild,type ~nd intact.! proleatet 
Dellt.~llofl 
wild-type 
Mut ~t+l I 
Mttt 4-I 
Mut J.10 
Amino m+id En,tyrn¢ ~<livlty tliodinll it= 
repl~'~ment (pmolJmint,#$] pep,mttn ~im~taw 
~10o I00% 
Ar#l'; ~+ Ly~ not ~t iw  100% 
Arlt~='~lt,  not a~:tlv< < $%' 
AInllll =+ Glu not aetlv~ )$~" 
+' P,~re¢rtt or re,covcr~l proleale dele~ted ill the ¢lu~l© ~fter pep~tl~ttlt 
A ,8,rose ill'tinily ehromalot~raphy a~ as~,ssed by den~ily seannlnm 
chromatography and cation exchange chromatography 
slightly improved the specific activity of the final en- 
zyme preparation (4200 pmol/min//~g), With both pro- 
cedures we obtained an enzyme which was 20-30% pure 
(PR concentration 10-18 nM) as determined by active 
site titration using compound 3of Grobelny et al. [25], 
a potent transition state inhibitor of HIV proteases. 
These enzyme preparations have been used, for develop. 
ing a solid phase assay [20], a continuous spec. 
trophotometric assay and enzyme kinetics [24] and for 
inhibitor studies [25,261. 
As described earlier [12,13], mutations in the second 
conserved region of the HIV-1 PR destroy the ability of 
this enzyme to cleave its substrate. Even a relatively 
minor change by replacing the Arg-87 with Lys (main- 
taining a positive charge on the side chain) did not show 
any specific proteolytic activity. We have shown earlier, 
that the product expressed in the mutants were identical 
in size to the wild-type product, and approximately 
equal amounts were observed after 230 rain of induction 
[12]. As demonstrated in Fig, 1, insert, Mat 3-11 binds 
to pepstatin A as well as the wild-type PR. The Western 
blot shows only one single band of 11 kDa, no non- 
specific signals have been observed with the preadsorb- 
ed antibody. Under identical conditions, the mutant 
protease derived from 4-1 and 5-10 were analyzed for 
their capacity to bind to pepstatin A agarose by dot 
blotting analysis. Apparently, Mut 5-10 binds weaker to 
pepstatin A, approximately 35°70 of Mut 5-10 PR was 
bound, and the majority of Mut 4-1 PR was found in 
the eft".:-.. . . . . . . . . . . .  ated by densitometric scanning of 
the dot blots shown in Fig. 2. The results are summariz- 
ed in Table I. 
The change of a positive to a negatively charged 
amino acid at position 87 (Mut 4-1) apparently leads to 
the loss of inhibitor binding ability, which may be caus- 
ed by conformational changes altering either the struc- 
ture of the binding pocket, or the dimerization, or both. 
However, the change of a neutral to a negatively charg- 
ed amino acid at position 88 (Mut 5-!0) still allowed 
binding of the inhibitor, assuming that this mutation 
has only a minor influence on the structure/conforma- 
tion of the enzyme. A more conservative mutation 
(Arg-87--, Lys) in the second conserved region may lead 
to minor ¢ilange~ in the micro-environmem of the 
¢leavatl¢ site preventtn it tile hydrolysi, of the substrate 
without ~ffeetinll the binding or the In. 
hlbitor/~ubstrate, whereas the mutations A~n.Rg~Glu 
and Arg.87 ~ Ght m~y cause con form;ttionttl ¢hanlleS of 
the secondary structure decreasing or aboli~hin~ the in,. 
hibitor/substrate bindintt, respectively, under the con- 
ditions used, Further characterization of these mutants 
by determining the substrate binding (Am) and 
dimerization (K,=) may give a better understancdina of 
the functional role of the Gly-ArlPAsn structural ele. 
ment of HIV-I proteases and in the design of specific 
inhibitors capable of' recolinizing the viral protease but 
not the related pepsin-like host proteases. Additionally, 
inhibitor affinity chromatography allows to screen and 
purify other mutated HIV proteases till capable of 
inhibitor-binding, While this manuscript was in 
preparation, another group reported the use of 
pepstatin A affinity chromatography for the purifica- 
tion of HIV-I and HIV-2 wild.type PRs [27]. 
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